https://www.selleckchem.com/products/Tubacin.html
A total of 20 subjects had severe haemophilia B. Three subjects experienced 7 treatment-related AEs; 3 experienced 4 ESIs. Median ABR was 4.5 and 1.1 in subjects who received predominantly on-demand (n=5) or prophylactic treatment (n=19), respectively; the overall median ABR for joint bleeding events was 0.0. Overall, nonacog alfa treatment effectively controlled bleeding events, with no new safety signals identified. These data support the safety and efficacy of nonacog alfa in routine clinical settings in children aged 6years. Ove
Like
Comment
Share
